--> --> -->


Mar 2022

Parenteral Products Package Testing with E-Scan HVLDmc

Parenteral Products Package Testing with E-Scan HVLDmc

For parenteral administration, compounded sterile preparations are often made from manufactured sterile materials. As a means of drug delivery, patients commonly require the administration of parenteral formulations. When compared to other methods of drug delivery, this method has both advantages and disadvantages. Nowadays, the ways of administration of new drugs are increasing all over the world. The range of possibilities for drug delivery containers must be reviewed on a regular basis, with the objective of improving compliance and delivery accuracy.

The packaging around a drug product is critical when establishing a new drug product or even re-facing an old one. There has also been an increase in the number of packaging formats for parenteral over the last ten years. Liquid-filled containers such as vials, ampoules, syringes, blow-fill seals, and auto-injectors, as well as containers filled with lyophilized products, are common parenteral packaging methods. Parenteral drugs are directly injected into the human body. Therefore, it is necessary to ensure the product quality of parenteral throughout its shelf life. Highly sensitive and reliable test methods are required. In this blog, we will discuss about parenteral product leak testing.

Why Use E-Scan HVLDmc for Testing Parenteral Products Packages?

E-Scan 655 is a revolutionary deterministic offline micro leak test equipment that inspects vials, syringes, and other liquid-filled parenteral products for container closure integrity using a new class of HVLD technology. The technique utilizes a non-contact, non-invasive test procedure that does not need sample preparation. E-Scan 655 is compatible with a variety of liquid-based products, including low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions, including vaccines. At high production rates, the offline E-Scan 655 approach may be converted from laboratory to 100 percent inline testing applications. The E-Scan 655 technology is a non-destructive MicroCurrent conductivity test technique for parenterals. This method exposes the packaging and product to a lower voltage than other conductivity-based solutions.

Using a series of electrode probes, the E-Scan tester scans a sealed non-conductive container. Glass, plastic, or poly laminate can be used to make the container. The liquid must be contained within the container or packet (minimum fill 30 percent). There is a resistance differential and a change in current flow if there is a pinhole, crack, or other flaw, indicating a container breach. The approximate position of the defect can be determined.

Benefits of E-Scan MicroCurrent technology

  • Non-destructive, non-invasive, and no sample preparation is required.
  • Greater accuracy and repeatability.
  • Lower voltage exposure eliminates risk to the product and environment.
  • Quick changeover and simple recipe set up to accommodate a wide range of products and applications.
  • E-Scan MicroCurrent technology is effective across all parenteral products, including extremely low conductivity liquids (WFI).
  • Listed in USP Chapter 1207> as a proposed methodology for parenteral liquid package inspection.
  • The inspection and validation process is simplified.

E-Scan HVLDmc is one of the highly effective CCI technologies for parenteral. It is applicable to pre-filled syringes, vials, cartridges, ampoules, BFS, bottles, and pouches. The technology has a rapid test cycle and is easy to use. PTI’s E-Scan 655 is a patent-pending technology that uses a unique mode of MicroCurrent HVLD technique that requires less than half of the voltage required by existing high voltage technologies. MicroCurrent HVLD technology can be applied from the R&D laboratory to automated 100% inline CCI inspection.

microcurrent hvld, container closure integrity, parenteral product leak testing, container closure integrity testing, cci technologies

Popular Blogs


CCIT for Pharmaceutical Package Integrity

Jul 23, 2021   |   2634

Container Closure Integrity Testing of pharmaceutical packaging ensures that the products remain intact throughout its shelf life or until it reaches the end user.

Why is Seal Integrity Testing of Medical Device Packaging Important

Jul 29, 2021   |   2393

For sterile medical devices, seal integrity testing ensures product efficacy, shelf-life stability, and microbial sterility. Airborne Ultrasound technology is a non-destructive Container Closure Integrity test method, capable of examining seal quality for defects.

A Guide to MicroCurrent HVLD Technology

Aug 05, 2021   |   2248

In the case of parenteral drug product containers, HVLD technology is ideal for CCI testing in cases where packaging is less conductive than the liquid within.

Evaluating Package Integrity Solutions for Vials

Nov 30, 2021   |   1993

CCI testing is a critical component of quality assurance for vials. The defects which cause a sterile vial to leak are not necessarily defects that will be detected.

Pre-filled Syringes Leak Detection with Vacuum Decay Vs MicroCurrent HVLD Test Methods

Nov 23, 2021   |   1957

Container Closure Integrity (CCI) can be challenged using various test methods, not all of which are equally capable of detecting leaks in the package.